Bicara Therapeutics financials
$18.61+0.27%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$155.6M | -$82.4M |
| Net income | -$137.9M | -$68.0M |
| Net margin | — | — |
| Diluted EPS | $-2.52 | $-4.05 |
| EBITDA | -$155.5M | -$82.3M |
| Operating cash flow | -$106.8M | -$74.8M |
| Free cash flow | -$107.1M | -$74.8M |
| Diluted shares | 54.7M | 16.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $96.7M | $489.7M |
| Short-term investments | $318.1M | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $431.0M | $510.0M |
| Total liabilities | $29.5M | $18.1M |
| Shareholders' equity | $401.5M | $491.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology